France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Swedish biotech Oncopeptides (Nasdaq Stockholm: ONCO) has entered into a partnership with Spanish pharmaceutical broker SD ...

GSK (LSE: GSK) posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax ...

The successful development of Frexalimab could positively impact Sanofi’s stock performance by enhancing its portfolio in the multiple sclerosis market, potentially increasing investor interest. As ...